An interventional study of BAP0527 and Blood Glucose Meter in Type 2 Diabetes Mellitus, sponsored by Astellas Pharma Inc. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Astellas Pharma Inc · Interventional and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Astellas Pharma Inc.
Among the 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc, this one is the 6th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 35th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 15 · Phase 4 5
First in 2007; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 128 across the 32 interventional studies, 10,050 across the 2 observational. Of the 35 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Diabetes Mellitus, Type 2 by Astellas Pharma Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The subjects of this study are patients with type 2 diabetes mellitus. The patients take part in dietetic therapy and exercise therapy, and also receive diabetes education to improve lifestyle habits, but since diet and exercise are lifestyle-based, it is generally difficult to make lifestyle changes and continue self-management for diabetes management.
The objective of this study is to determine whether the use of a diabetes treatment support system (BAP0527 and blood glucose meter, hereafter, this product) would allow type 2 diabetes mellitus patients to control their blood glucose well.
BAP0527 is a modified Japanese version of BlueStar®, a smartphone application approved by the U.S. Food and Drug Administration to manage and support the treatment of diabetes in adults. The blood glucose meter is a device that measures blood glucose levels from fingertips and palm blood using a dedicated paracentesis device (a device used to draw blood). In this study, BAP0527 will be used in conjunction with the blood glucose meter.
This study is open-label. Open-label means that subjects participating in this study are aware of whether they use this product in addition to their daily practice and treatment. Whether a subject uses this product or not is determined randomly. The subjects in the group using this product will be required to install BAP0527 on their smartphones and record their lifestyle habits (diet, exercise, sleep), medication compliance, blood pressure, pulse, weight, and also blood glucose levels measured by the blood glucose meter. In addition, they will review lifestyle habits according to the messages sent by BAP0527 based on the inputs, and watch educational contents. On the other hand, subjects in the group not using this product will continue to receive the treatment they have taken before participating in the study.
The study period is approximately 10 months. During this period, a subject will visit a hospital approximately 12 times. For subjects in the group who use this product, the duration of use of this product is approximately 6 months.
When a subject visits a hospital, a study doctor will confirm if the subject has a health problem. In addition, laboratory test, body temperature, blood pressure, and pulse will be confirmed. Blood/urine samples will be collected from subjects for laboratory tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants having and using a smartphone device meeting the following operating system requirements as of visit 1
Female participant is not pregnant and at least 1 of the following conditions apply:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants use the BAP0527 and Blood Glucose Meter in addition to the usual treatment at each site.
Device: BAP0527 · Device: Blood Glucose Meter
Participants receive the usual treatment they received before participating in the study.
Participants will continuously use BAP0527, while measuring their daily blood glucose levels using the blood glucose meter, and will input daily self-management records such as lifestyle habits (diet, exercise, sleep), use of medication and measurements (blood glucose level, blood pressure, pulse rate, body weight) into BAP0527.
Participants measure blood glucose using a blood glucose meter in daily life.
Also known as: ACCU-CHEK® Guide Me
Change From Baseline in HbA1c Level at Week 24
The change from Baseline in HbA1c level at Week 24 (central lab measurement) was defined by the formula: HbA1c level at Week 24 - HbA1c level at Baseline. A negative change indicated a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were missing at random (MAR).
Time frame: Baseline and Week 24
Change From Baseline in HbA1c Level at Each Assessment Timepoint (Except Week 24)
The change from Baseline in HbA1c level at each assessment time point (except Week 24) (central lab measurement) was defined by the formula: HbA1c level at each assessment time point (Weeks 4 to 20) - HbA1c level at Baseline. A negative change indicated a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at each assessment time point (except Week 24) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
Time frame: Baseline and Weeks 4, 8, 12, 16, and 20
Percentage of Participants With a Baseline HbA1c Level ≥ 8.0% Who Achieved an HbA1c Level < 8.0% at Week 24
The percentage of participants with a Baseline HbA1c level ≥ 8.0% who achieved an HbA1c level \< 8.0% at Week 24 (central lab measurement) was defined by the formula: (number of participants with an HbA1c level ≥ 8.0% at Baseline and an HbA1c level \< 8.0% at Week 24) / (Number of participants with an HbA1c level ≥ 8.0% at Baseline). If the HbA1c level at Week 24 was missing, the imputed HbA1c level under the assumption of MAR was used.
Time frame: Week 24
Change From Baseline Value in Fasting Blood Glucose Level at Week 24
The change from Baseline in fasting blood glucose level at Week 24 (central lab measurement) was defined by the formula: fasting blood glucose level at Week 24 - fasting blood glucose level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the fasting blood glucose level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
Time frame: Baseline and Week 24
Change From Baseline Value in Fasting Insulin Level at Week 24
The change from Baseline in fasting insulin level at Week 24 (central lab measurement) was defined by the formula: fasting insulin level at Week 24 - fasting insulin level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the fasting insulin level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
Time frame: Baseline and Week 24
Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 24, Relative to Antidiabetic Use at Baseline
The percentage of participants with a decreased dose of antidiabetics or reduced number of antidiabetics by Week 24, relative to antidiabetic use at Baseline, was defined by the formula: (number of participants who use antidiabetics at Baseline and then have a decreased dose of antidiabetics or reduced number of antidiabetics by Week 24 relative to antidiabetic use at Baseline) / (number of participants who use antidiabetics at Baseline). A decreased dose of antidiabetics or reduced number of antidiabetics was defined as cases where the dose of antidiabetics is decreased or the number of antidiabetics is reduced at least once by Week 24 compared with the dose or number of antidiabetics at Baseline.
Time frame: Baseline up to Week 24
Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 24, Relative to Antidiabetic Use at Baseline
The percentage of participants with an increased dose of antidiabetics or newly started hypoglycemics by Week 24, relative to antidiabetic use at Baseline, was defined by the formula: (number of participants in the FAS with an increased dose of antidiabetics or newly started hypoglycemics by Week 24 relative to antidiabetic use at Baseline) / (number of participants in the FAS). An increased dose of antidiabetics or newly started hypoglycemics was defined as cases where the dose of antidiabetics is increased at least once or a hypoglycemic is added at least once by Week 24 compared with the dose of antidiabetics or the number of hypoglycemics at Baseline.
Time frame: Baseline up to Week 24
Change From Baseline in HbA1c Level in the Follow-up Period
The change from Baseline in HbA1c level at each assessment time point in the follow-up period (central lab measurement) is defined by the formula: HbA1c level at each assessment time point (Weeks 28 to 36) - HbA1c level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at each assessment time point (Weeks 28 to 36) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
Time frame: Baseline and Weeks 28, 32 and 36
Change From Week 24 in HbA1c Level in the Follow-up Period
The change from Week 24 in HbA1c level at each assessment time point in the follow-up period (central lab measurement) is defined by the formula: HbA1c level at each assessment time point (Weeks 28 to 36) - HbA1c level at Week 24. A negative change indicates a reduction/improvement from Week 24 (i.e. a favorable outcome). If the HbA1c level at each assessment time point (Weeks 28 to 36) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
Time frame: Week 24 and Weeks 28, 32 and 36
Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24
The percentage of participants with a decreased dose of antidiabetics or reduced number of antidiabetics by Week 12 of the follow-up period, relative to antidiabetic use at Week 24, is defined by the formula: (number of participants who start the follow-up, use antidiabetics at Week 24, and have a decreased dose of antidiabetics or reduced number of antidiabetics between Week 28 and Week 36 relative to antidiabetic use at Week 24) / (number of participants who start the follow-up and use antidiabetics at Week 24). A decreased dose of antidiabetics or reduced number of antidiabetics was defined as cases where the dose of antidiabetics was decreased or the number of antidiabetics was reduced at least once between Week 28 and Week 36 compared with the dose or number of antidiabetics at Week 24.
Time frame: Week 24 up to Week 36
Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24
The percentage of participants with an increased dose of antidiabetics or newly started hypoglycemics by Week 12 of the follow-up period, relative to antidiabetic use at Week 24, is defined by the formula: (Number of participants in the FAS2 with an increased dose of antidiabetics or newly started hypoglycemics between Week 28 and Week 36 relative to antidiabetic use at Week 24) / (Number of participants in the FAS2). An increased dose of antidiabetics or newly started hypoglycemics is defined as cases where the dose of antidiabetics is increased at least once or a hypoglycemic is added at least once between Week 28 and Week 36 compared with the dose of antidiabetics or the number of hypoglycemics at Week 24.
Time frame: Week 24 up to Week 36
Number of Participants With Adverse Events (AEs)
An AE is any untoward medical occurrence in a patient, clinical study participant, user or other person, temporally associated with the use of study intervention, whether or not considered related to the study intervention. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the device used in the clinical study, if applicable, and events related to the (study) procedures. A device-related AE is an AE that is related to the use of a device used in the clinical study. This includes AEs caused by an omission in the instruction manual for the use, dispensing or operation of a device used in the clinical study, or a deficiency in the device used in the clinical study. It also includes AEs occurring due to the improper use (including intentional improper use) of a device used in the clinical study.
Time frame: From Day 1 up to Week 36
Number of Participants Who Experienced Device Deficiency
A deficiency in a device is the situation where a device used in the clinical study is broadly in a poor condition in relation to quality, safety or performance, such as device damage or malfunctions, regardless of whether this occurs at the stage of design, dispensing, storage or use.
Time frame: From Day 1 up to Week 24
Participants of either gender, of at least 18 years old of age, with the diagnosis of type 2 diabetes mellitus were enrolled in this study.
| Milestone | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Started | 125 | 123 |
| Completed | 122 | 121 |
| Not completed | 3 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol deviation | 1 | 1 |
| Milestone | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Started | 122 | 121 |
| Completed | 122 | 117 |
| Not completed | 0 | 4 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 2 |
The change from Baseline in HbA1c level at Week 24 (central lab measurement) was defined by the formula: HbA1c level at Week 24 - HbA1c level at Baseline. A negative change indicated a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were missing at random (MAR).
| change in HbA1c percentage | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Change From Baseline in HbA1c Level at Week 24 | -0.38 ± 0.08 | -0.49 ± 0.08 |
The change from Baseline in HbA1c level at each assessment time point (except Week 24) (central lab measurement) was defined by the formula: HbA1c level at each assessment time point (Weeks 4 to 20) - HbA1c level at Baseline. A negative change indicated a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at each assessment time point (except Week 24) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
| change in HbA1c percentage | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Week 4 | -0.06 ± 0.03 | -0.26 ± 0.03 |
| Week 8 | -0.13 ± 0.05 | -0.36 ± 0.05 |
| Week 12 | -0.21 ± 0.07 | -0.44 ± 0.07 |
| Week 16 | -0.22 ± 0.07 | -0.47 ± 0.07 |
| Week 20 | -0.31 ± 0.08 | -0.46 ± 0.08 |
The percentage of participants with a Baseline HbA1c level ≥ 8.0% who achieved an HbA1c level \< 8.0% at Week 24 (central lab measurement) was defined by the formula: (number of participants with an HbA1c level ≥ 8.0% at Baseline and an HbA1c level \< 8.0% at Week 24) / (Number of participants with an HbA1c level ≥ 8.0% at Baseline). If the HbA1c level at Week 24 was missing, the imputed HbA1c level under the assumption of MAR was used.
| percentage of participants | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Percentage of Participants With a Baseline HbA1c Level ≥ 8.0% Who Achieved an HbA1c Level < 8.0% at Week 24 | 33.5 | 42.0 |
The change from Baseline in fasting blood glucose level at Week 24 (central lab measurement) was defined by the formula: fasting blood glucose level at Week 24 - fasting blood glucose level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the fasting blood glucose level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
| mg/dL | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Change From Baseline Value in Fasting Blood Glucose Level at Week 24 | -17.1 ± 3.9 | -17.7 ± 3.9 |
The change from Baseline in fasting insulin level at Week 24 (central lab measurement) was defined by the formula: fasting insulin level at Week 24 - fasting insulin level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the fasting insulin level at Week 24 was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
| uIU/mL | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Change From Baseline Value in Fasting Insulin Level at Week 24 | 0.068 ± 0.764 | 0.270 ± 0.763 |
The percentage of participants with a decreased dose of antidiabetics or reduced number of antidiabetics by Week 24, relative to antidiabetic use at Baseline, was defined by the formula: (number of participants who use antidiabetics at Baseline and then have a decreased dose of antidiabetics or reduced number of antidiabetics by Week 24 relative to antidiabetic use at Baseline) / (number of participants who use antidiabetics at Baseline). A decreased dose of antidiabetics or reduced number of antidiabetics was defined as cases where the dose of antidiabetics is decreased or the number of antidiabetics is reduced at least once by Week 24 compared with the dose or number of antidiabetics at Baseline.
| percentage of participants | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 24, Relative to Antidiabetic Use at Baseline | 13.7 | 15.8 |
The percentage of participants with an increased dose of antidiabetics or newly started hypoglycemics by Week 24, relative to antidiabetic use at Baseline, was defined by the formula: (number of participants in the FAS with an increased dose of antidiabetics or newly started hypoglycemics by Week 24 relative to antidiabetic use at Baseline) / (number of participants in the FAS). An increased dose of antidiabetics or newly started hypoglycemics was defined as cases where the dose of antidiabetics is increased at least once or a hypoglycemic is added at least once by Week 24 compared with the dose of antidiabetics or the number of hypoglycemics at Baseline.
| percentage of participants | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 24, Relative to Antidiabetic Use at Baseline | 40.8 | 29.3 |
The change from Baseline in HbA1c level at each assessment time point in the follow-up period (central lab measurement) is defined by the formula: HbA1c level at each assessment time point (Weeks 28 to 36) - HbA1c level at Baseline. A negative change indicates a reduction/improvement from Baseline (i.e. a favorable outcome). If the HbA1c level at each assessment time point (Weeks 28 to 36) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
| change in HbA1c percentage | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Week 28 | -0.42 ± 0.08 | -0.39 ± 0.08 |
| Week 32 | -0.41 ± 0.08 | -0.29 ± 0.08 |
| Week 36 | -0.37 ± 0.08 | -0.27 ± 0.09 |
The change from Week 24 in HbA1c level at each assessment time point in the follow-up period (central lab measurement) is defined by the formula: HbA1c level at each assessment time point (Weeks 28 to 36) - HbA1c level at Week 24. A negative change indicates a reduction/improvement from Week 24 (i.e. a favorable outcome). If the HbA1c level at each assessment time point (Weeks 28 to 36) was missing, the analysis was conducted using an MMRM under the assumption that data were MAR.
| change in HbA1c percentage | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Week 28 | -0.04 ± 0.03 | 0.07 ± 0.03 |
| Week 32 | -0.02 ± 0.05 | 0.17 ± 0.05 |
| Week 36 | 0.02 ± 0.06 | 0.19 ± 0.07 |
The percentage of participants with a decreased dose of antidiabetics or reduced number of antidiabetics by Week 12 of the follow-up period, relative to antidiabetic use at Week 24, is defined by the formula: (number of participants who start the follow-up, use antidiabetics at Week 24, and have a decreased dose of antidiabetics or reduced number of antidiabetics between Week 28 and Week 36 relative to antidiabetic use at Week 24) / (number of participants who start the follow-up and use antidiabetics at Week 24). A decreased dose of antidiabetics or reduced number of antidiabetics was defined as cases where the dose of antidiabetics was decreased or the number of antidiabetics was reduced at least once between Week 28 and Week 36 compared with the dose or number of antidiabetics at Week 24.
| percentage of participants | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Percentage of Participants With a Decreased Dose of Antidiabetics or Reduced Number of Antidiabetics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24 | 8.5 | 4.2 |
The percentage of participants with an increased dose of antidiabetics or newly started hypoglycemics by Week 12 of the follow-up period, relative to antidiabetic use at Week 24, is defined by the formula: (Number of participants in the FAS2 with an increased dose of antidiabetics or newly started hypoglycemics between Week 28 and Week 36 relative to antidiabetic use at Week 24) / (Number of participants in the FAS2). An increased dose of antidiabetics or newly started hypoglycemics is defined as cases where the dose of antidiabetics is increased at least once or a hypoglycemic is added at least once between Week 28 and Week 36 compared with the dose of antidiabetics or the number of hypoglycemics at Week 24.
| percentage of participants | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Percentage of Participants With an Increased Dose of Antidiabetics or Newly Started Hypoglycemics by Week 12 of the Follow-up Period, Relative to Antidiabetic Use at Week 24 | 17.2 | 10.8 |
An AE is any untoward medical occurrence in a patient, clinical study participant, user or other person, temporally associated with the use of study intervention, whether or not considered related to the study intervention. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the device used in the clinical study, if applicable, and events related to the (study) procedures. A device-related AE is an AE that is related to the use of a device used in the clinical study. This includes AEs caused by an omission in the instruction manual for the use, dispensing or operation of a device used in the clinical study, or a deficiency in the device used in the clinical study. It also includes AEs occurring due to the improper use (including intentional improper use) of a device used in the clinical study.
| count of participants | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 99 | 95 |
A deficiency in a device is the situation where a device used in the clinical study is broadly in a poor condition in relation to quality, safety or performance, such as device damage or malfunctions, regardless of whether this occurs at the stage of design, dispensing, storage or use.
| count of participants | Usual Treatment Group | BAP0527 Group |
|---|---|---|
| Number of Participants Who Experienced Device Deficiency | — | 31 |
Collected over All-cause mortality (ACM): From randomization up to 36 weeks Serious Adverse events (SAEs) and non-SAEs: From first dose up to 36 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period: Usual Treatment Group | 0/125 (0%) | 5/125 (4%) | 33/125 (26.4%) |
| Treatment Period: BAP0527 Group | 0/123 (0%) | 4/123 (3.3%) | 32/123 (26%) |
| Follow-up Period: Usual Treatment Group | 0/122 (0%) | 0/122 (0%) | 26/122 (21.3%) |
| Follow-up Period: BAP0527 Group | 1/121 (0.8%) | 2/121 (1.7%) | 15/121 (12.4%) |
| Event | Treatment Period: Usual Treatment Group | Treatment Period: BAP0527 Group | Follow-up Period: Usual Treatment Group | Follow-up Period: BAP0527 Group |
|---|---|---|---|---|
| DeathGeneral disorders | 0/125 | 0/123 | 0/122 | 1/121 |
| PyelonephritisInfections and infestations | 0/125 | 0/123 | 0/122 | 1/121 |
| Eyelid ptosisEye disorders | 0/125 | 1/123 | 0/122 | 0/121 |
| Humerus fractureInjury, poisoning and procedural complications | 0/125 | 1/123 | 0/122 | 0/121 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/125 | 1/123 | 0/122 | 0/121 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/125 | 1/123 | 0/122 | 0/121 |
| InfluenzaInfections and infestations | 1/125 | 0/123 | 0/122 | 0/121 |
| PneumoniaInfections and infestations | 1/125 | 0/123 | 0/122 | 0/121 |
| Cervical vertebral fractureInjury, poisoning and procedural complications | 1/125 | 0/123 | 0/122 | 0/121 |
| Foot fractureInjury, poisoning and procedural complications | 1/125 | 0/123 | 0/122 | 0/121 |
| Event | Treatment Period: Usual Treatment Group | Treatment Period: BAP0527 Group | Follow-up Period: Usual Treatment Group | Follow-up Period: BAP0527 Group |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 26/125 | 24/123 | 18/122 | 13/121 |
| InfluenzaInfections and infestations | 4/125 | 7/123 | 5/122 | 1/121 |
| DiarrhoeaGastrointestinal disorders | 7/125 | 4/123 | 4/122 | 2/121 |
Randomized Analysis Set included all participants who completed screening and were randomized. Participants were analyzed according to the treatment group to which they were randomized.
| Age, Continuous(Years) | Usual Treatment Group | BAP0527 Group | Total |
|---|---|---|---|
| Mean | 55.9 ± 11.2 | 56.3 ± 10.5 | 56.1 ± 10.9 |
| Sex: Female, Male(Participants) | Usual Treatment Group | BAP0527 Group | Total |
|---|---|---|---|
| Female | 36 | 36 | 72 |
| Male | 89 | 87 | 176 |
| Ethnicity (NIH/OMB)(Participants) | Usual Treatment Group | BAP0527 Group | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 125 | 123 | 248 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Usual Treatment Group | BAP0527 Group | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 125 | 123 | 248 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Body Mass Index (BMI)(Participants) | Usual Treatment Group | BAP0527 Group | Total |
|---|---|---|---|
| <25 kg/m^2 | 46 | 45 | 91 |
| >=25 kg/m^2 | 79 | 78 | 157 |
| Hemoglobin A1c (HbA1c)(HbA1c percentage) | Usual Treatment Group | BAP0527 Group | Total |
|---|---|---|---|
| Mean | 8.53 ± 0.59 | 8.60 ± 0.57 | 8.56 ± 0.58 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from Feb 2024 to primary completion in Jul 2025, 16 months.
Results were first posted in Sep 2026, 1 year 2 months after primary completion. A results delay was requested in Jun 2026.
Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's 16 months is close to that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.